Neoplasms Lung clinical trials

Explore recruiting neoplasms lung clinical trials.

Recruiting neoplasms lung studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Neoplasms Lung trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), compared with Topotecan in Participants with Relapsed Small Cell Lung Cancer (SCLC)

Hungary, France, Portugal, Greece, Sweden, Ireland +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Neoplasms Lung trials by city

Neoplasms Lung in Toronto Neoplasms Lung in Vancouver Neoplasms Lung in Montreal Neoplasms Lung in Calgary Neoplasms Lung in Edmonton Neoplasms Lung in Ottawa Neoplasms Lung in Winnipeg Neoplasms Lung in Quebec City Neoplasms Lung in Hamilton Neoplasms Lung in Kitchener Neoplasms Lung in London Neoplasms Lung in Halifax Neoplasms Lung in New York Neoplasms Lung in Los Angeles Neoplasms Lung in Chicago Neoplasms Lung in Houston

Neoplasms Lung clinical trials

Recruiting neoplasms lung studies right now

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies

Q702 for the Treatment of Patients With Hematologic Malignancies

Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC

A Study of Intensity-Modulated Pleural Radiation Therapy (IMPRINT) in People With Thymic Cancer That Has Spread to the Lining of the Lungs and Chest

Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer

Plasma Metabolomics as a Tool to Distinguish PET-positive Malignant From PET-positive Benign Nodules

Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

AB122 Platform Study

A Prospective Phase II Study of Postoperative Concurrent Chemoradiotherapy in Patients With Intrahepatic Cholangiocarcinoma

Also recruiting in Europe

Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), compared with Topotecan in Participants with Relapsed Small Cell Lung Cancer (SCLC)

Neoplasms Lung trials by city

Other conditions